ORBIO ORBIO

Oncotherapy Revolution by L-Glucose

Oncotherapy Revolution
   By Isomer Organics

ABOUT

Delivering a therapeutic drug for intractable cancer to society with L-glucose, which is highly selective for cancer cells.

We are a medical startup company founded in Kyoto in 2018 with the goal of bringing a therapeutic drug for intractable cancer to society. We are researching cancer treatment technologies and creating cancer diagnostic and therapeutic drugs so that we can help patients suffering from cancer as soon as possible.

CORPORATE

MISSION

  • 1 1

    Leading patients with intractable cancer to a complete cure.

    We aim to realize a new anti-cancer drug with L-glucose bound Orbio-molecules. We deliver the hope of complete cure beyond the diversity of intractable cancer.

  • 2 2

    Introducing a new treatment modality for cancer therapy.

    We will implement “cancer-specific cell therapy” using L-glucose as a drug delivery system (DDS), which shows unprecedented high selectivity in cancer treatment.

TECHNOLOGY

VALUE

  • 高く大きい志 高く大きい志
  • 革新をかたちにする技術 革新をかたちにする技術
  • 失敗を恐れず挑戦する行動 失敗を恐れず挑戦する行動
  • 謙虚、誠実、真摯な姿勢 謙虚、誠実、真摯な姿勢

TEAM

  • 山口 栄一

    Dr. EIICHI YAMAGUCHI
    CEO

    Professor Emeritus, Kyoto University
    Doctor of Science
    Vice-President of The Japan Academic Society for Ventures and Entrepreneurs

  • 飯島 秀樹

    Dr. HIDEKI IIJIMA
    Co-CEO/COO

    Lecturer, the Graduate School of Medicine, Hirosaki University
    Doctor of Engineering
    Ph.D. in Management of Innovative Management

  • 山田 勝也

    Dr. KATSUYA YAMADA
    CMO

    ORBIO-Chaired Professor, Department of Molecular Transport, Hirosaki University Graduate School of Medicine
    Ph.D. in Medicine; Councilor of the Physiological Society of Japan
    Councilor of the Physiological Society of Japan

TEAM

NEWS

To List

This website uses cookies.Please agree to the acquisition and use of cookies based on the personal information protection policy.

ACCEPT